These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26406146)

  • 21. Nonmotor gastrointestinal disorders in older patients with Parkinson's disease: is there hope?
    Georgescu D; Ancusa OE; Georgescu LA; Ionita I; Reisz D
    Clin Interv Aging; 2016; 11():1601-1608. PubMed ID: 27956826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson's disease.
    Barboza JL; Okun MS; Moshiree B
    Expert Opin Pharmacother; 2015; 16(16):2449-64. PubMed ID: 26374094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sialorrhea in patients with Parkinson's disease: safety and administration of botulinum neurotoxin.
    Egevad G; Petkova VY; Vilholm OJ
    J Parkinsons Dis; 2014; 4(3):321-6. PubMed ID: 24919823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease.
    Santos-García D; de la Fuente-Fernández R
    J Neurol Sci; 2013 Sep; 332(1-2):136-40. PubMed ID: 23890935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonmotor symptoms in nursing home residents with Parkinson's disease: prevalence and effect on quality of life.
    Weerkamp NJ; Tissingh G; Poels PJ; Zuidema SU; Munneke M; Koopmans RT; Bloem BR
    J Am Geriatr Soc; 2013 Oct; 61(10):1714-21. PubMed ID: 24117286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastrointestinal dysfunction in Parkinson's disease.
    Lubomski M; Davis RL; Sue CM
    J Neurol; 2020 May; 267(5):1377-1388. PubMed ID: 31989280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment approaches of gastrointestinal dysfunction in Parkinson's disease, therapeutical options and future perspectives.
    Woitalla D; Goetze O
    J Neurol Sci; 2011 Nov; 310(1-2):152-8. PubMed ID: 21798561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of non-motor symptoms on health-related quality of life in Parkinson's disease].
    Dong H; Liu C; Hu X
    Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(11):813-5. PubMed ID: 24854746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The heterogeneity of non-motor symptoms of Parkinson's disease.
    Zhang N; Liu W; Ye M; Cohen AD; Zhang Y
    Neurol Sci; 2015 Apr; 36(4):577-84. PubMed ID: 25376559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A practical review of gastrointestinal manifestations in Parkinson's disease.
    Su A; Gandhy R; Barlow C; Triadafilopoulos G
    Parkinsonism Relat Disord; 2017 Jun; 39():17-26. PubMed ID: 28258927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease.
    Leta V; Klingelhoefer L; Longardner K; Campagnolo M; Levent HÇ; Aureli F; Metta V; Bhidayasiri R; Chung-Faye G; Falup-Pecurariu C; Stocchi F; Jenner P; Warnecke T; Ray Chaudhuri K;
    Eur J Neurol; 2023 May; 30(5):1465-1480. PubMed ID: 36757008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parkinson's Disease and Diabetes Mellitus: Synergistic Effects on Pathophysiology and GI Motility.
    Yan Y; Shimoga D; Sharma A
    Curr Gastroenterol Rep; 2023 May; 25(5):106-113. PubMed ID: 37067721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease.
    Todorova A; Ray Chaudhuri K
    Parkinsonism Relat Disord; 2013 Dec; 19(12):1073-8. PubMed ID: 24051336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The management of gastrointestinal symptoms in Parkinson's disease.
    Salat-Foix D; Suchowersky O
    Expert Rev Neurother; 2012 Feb; 12(2):239-48. PubMed ID: 22288679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment.
    Chaudhuri KR; Schapira AH
    Lancet Neurol; 2009 May; 8(5):464-74. PubMed ID: 19375664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MitoPark transgenic mouse model recapitulates the gastrointestinal dysfunction and gut-microbiome changes of Parkinson's disease.
    Ghaisas S; Langley MR; Palanisamy BN; Dutta S; Narayanaswamy K; Plummer PJ; Sarkar S; Ay M; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Neurotoxicology; 2019 Dec; 75():186-199. PubMed ID: 31505196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influencing effect of non-motor symptom clusters on quality of life in Parkinson's disease.
    Kim SR; So HY; Choi E; Kang JH; Kim HY; Chung SJ
    J Neurol Sci; 2014 Dec; 347(1-2):310-5. PubMed ID: 25466694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gastrointestinal Dysfunction in Parkinson's Disease.
    Safarpour D; Sharzehi K; Pfeiffer RF
    Drugs; 2022 Feb; 82(2):169-197. PubMed ID: 35076890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact and management of nonmotor symptoms of Parkinson's disease.
    Lyons KE; Pahwa R
    Am J Manag Care; 2011 Oct; 17 Suppl 12():S308-14. PubMed ID: 22087551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment options for non-motor symptoms in late-stage Parkinson's disease.
    Coelho M; Ferreira J; Rosa M; Sampaio C
    Expert Opin Pharmacother; 2008 Mar; 9(4):523-35. PubMed ID: 18312155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.